Literature DB >> 17059579

Extended coagulation profiles of healthy baboons and of baboons rejecting GT-KO pig heart grafts.

Mohamed Ezzelarab1, Andrea Cortese-Hassett, David K C Cooper, Mark H Yazer.   

Abstract

INTRODUCTION: Derangements of coagulation, e.g. thrombotic microangiopathy (TM) and disseminated intravascular coagulation (DIC), limit the success of pig-to-baboon organ transplantation. Studies have investigated the coagulation profile in baboons post-xenotransplantation (XTx), but an extended coagulation profile of healthy baboons pre-XTx has not been reported.
METHODS: Blood was drawn from nine healthy male baboons (approximate age 5 yr, mean weight 15 kg) that had not undergone any prior surgical or therapeutic procedures. An extended coagulation profile, consisting of markers of thrombin activation, fibrinolysis, endothelial activation, the protein C pathway, and overall reactive state, was investigated by a reference coagulation laboratory, using tests for human plasma. The mean value +/- SD was calculated for 18 parameters (analytes); values outside of the mean +/- 2 SD were excluded. Three baboons subsequently underwent transplantation with hearts from GT-KO pigs, and received either no therapy (B24603), CVF (B25003), or CVF + leflunomide (B24903), and their extended coagulation parameters were followed.
RESULTS: For 14 of the 18 analytes, the human reference range reflected the coagulation status of healthy baboons. Exceptions included thrombin/antithrombin complex and fibrinopeptide A, which were elevated compared with the human reference range, while plasminogen activity was lower. The human assay failed to detect baboon plasminogen activator inhibitor-1. Immediately after GT-KO pig heart transplantation, the untreated B24603 demonstrated a coagulation profile consistent with its postoperative clinical status; DIC was not apparent, and the heart was electively excised within 2.5 h. In B25003 and B24903, that rejected their grafts on days 8 and 12, respectively, the coagulation profile showed evidence of DIC, particularly in B24903, which was clinically coagulopathic by this time.
CONCLUSIONS: (i) The human reference range of extended coagulation parameters forms a basis for studies in baboons, with a few exceptions. (ii) Antibody-mediated rejection of GT-KO pig hearts in baboons can be associated with laboratory and clinical evidence of DIC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059579     DOI: 10.1111/j.1399-3089.2006.00342.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  10 in total

1.  Comparison of hematologic, biochemical, and coagulation parameters in α1,3-galactosyltransferase gene-knockout pigs, wild-type pigs, and four primate species.

Authors:  Burcin Ekser; John Bianchi; Suyapa Ball; Hayato Iwase; Anneke Walters; Mohamed Ezzelarab; Massimiliano Veroux; Bruno Gridelli; Robert Wagner; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2012-11-12       Impact factor: 3.907

2.  Human T-cell proliferation in response to thrombin-activated GTKO pig endothelial cells.

Authors:  Corin Ezzelarab; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2012-09-13       Impact factor: 3.907

3.  Hepatic function after genetically engineered pig liver transplantation in baboons.

Authors:  Burcin Ekser; Gabriel J Echeverri; Andrea Cortese Hassett; Mark H Yazer; Cassandra Long; Michael Meyer; Mohamed Ezzelarab; Chih Che Lin; Hidetaka Hara; Dirk J van der Windt; Eefje M Dons; Carol Phelps; David Ayares; David K C Cooper; Bruno Gridelli
Journal:  Transplantation       Date:  2010-09-15       Impact factor: 4.939

4.  Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation.

Authors:  Burcin Ekser; Chih C Lin; Cassandra Long; Gabriel J Echeverri; Hidetaka Hara; Mohamed Ezzelarab; Vladimir Y Bogdanov; Donna B Stolz; Keiichi Enjyoji; Simon C Robson; David Ayares; Anthony Dorling; David K C Cooper; Bruno Gridelli
Journal:  Transpl Int       Date:  2012-05-30       Impact factor: 3.782

5.  Systemic inflammation in xenograft recipients precedes activation of coagulation.

Authors:  Mohamed B Ezzelarab; Burcin Ekser; Agnes Azimzadeh; Chih Che Lin; Yuming Zhao; Rachael Rodriguez; Gabriel J Echeverri; Hayato Iwase; Cassandra Long; Hidetaka Hara; David Ayares; Richard N Pierson; Angus W Thomson; David K Cooper
Journal:  Xenotransplantation       Date:  2014-09-11       Impact factor: 3.907

Review 6.  Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.

Authors:  Miriam Manook; Jean Kwun; Steven Sacks; Anthony Dorling; Nizam Mamode; Stuart Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2018-02-10       Impact factor: 3.943

7.  Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition.

Authors:  Hayato Iwase; Burcin Ekser; Hidetaka Hara; Carol Phelps; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2013-11-05       Impact factor: 3.907

8.  The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients.

Authors:  Mohamed Ezzelarab; Bertha Garcia; Agnes Azimzadeh; Hongtao Sun; Chih Che Lin; Hidetaka Hara; Sean Kelishadi; Tianshu Zhang; Yih Jyh Lin; Hao-Chi Tai; Robert Wagner; Jnanesh Thacker; Noriko Murase; Kenneth McCurry; Rolf N Barth; David Ayares; Richard N Pierson; David K C Cooper
Journal:  Transplantation       Date:  2009-03-27       Impact factor: 4.939

Review 9.  Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?

Authors:  Christopher G A McGregor; Guerard W Byrne
Journal:  J Immunol Res       Date:  2017-11-07       Impact factor: 4.818

10.  Complications of umbilical artery catheterization in a model of extreme prematurity.

Authors:  R M McAdams; V T Winter; D C McCurnin; J J Coalson
Journal:  J Perinatol       Date:  2009-06-25       Impact factor: 2.521

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.